Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis

Universitaire Ziekenhuizen KU Leuven

Status: Completed

Conditions: Invasive Pulmonary Aspergillosis

Study type: Observational

Funder types: Other

Identifiers

NCT01247142

S52756

Details and patient eligibility

About

The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.

Full description

Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.

Enrollment: 24 patients

Sex: All

Ages: 16+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• hospitalisation in the hematology or intensive care department
• age > 16 years
• informed consent
• proven or probable IPA (EORTC/ MSG criteria)
• galactomannan positivity in BAL or serum

Exclusion criteria

• age < 16 years

Trial design

24 participants in 2 patient groups

Invasive pulmonary aspergillosis (IPA)

Description:

Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)

Controls

Description:

Patients without signs of infection.